Short Interest in First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Decreases By 37.5%

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 500 shares, a decrease of 37.5% from the February 28th total of 800 shares. Based on an average trading volume of 2,700 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the stock are sold short.

Hedge Funds Weigh In On First Trust Nasdaq Pharmaceuticals ETF

Hedge funds have recently bought and sold shares of the stock. LPL Financial LLC boosted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 9.3% during the fourth quarter. LPL Financial LLC now owns 55,876 shares of the company’s stock valued at $1,507,000 after acquiring an additional 4,776 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in First Trust Nasdaq Pharmaceuticals ETF by 17.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 16,403 shares of the company’s stock valued at $442,000 after purchasing an additional 2,384 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 13.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,173 shares of the company’s stock worth $382,000 after purchasing an additional 1,633 shares during the last quarter. Finally, Vivaldi Capital Management LP grew its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 15.6% during the fourth quarter. Vivaldi Capital Management LP now owns 8,677 shares of the company’s stock worth $243,000 after buying an additional 1,171 shares in the last quarter.

First Trust Nasdaq Pharmaceuticals ETF Price Performance

FTXH traded down $0.04 during midday trading on Friday, reaching $27.33. 1,868 shares of the company’s stock were exchanged, compared to its average volume of 3,806. The business’s 50-day moving average price is $27.82 and its 200 day moving average price is $27.98. The stock has a market capitalization of $13.66 million, a PE ratio of 21.02 and a beta of 0.70. First Trust Nasdaq Pharmaceuticals ETF has a 1-year low of $25.73 and a 1-year high of $29.72.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Thursday, March 27th will be issued a dividend of $0.0992 per share. This represents a $0.40 dividend on an annualized basis and a yield of 1.45%. The ex-dividend date of this dividend is Thursday, March 27th.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.